Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085476 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| SCHEMBL14261286 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| SCHEMBL24590305 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| SCHEMBL57306 | 0.97 | — | — | |
| SCHEMBL8648295 | 0.97 | — | — | |
| SCHEMBL21954031 | 0.97 | HRH3 (0.38) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| Hydrochloric Acid SCHEMBL2139284 | 0.94 | PRKCG (0.40) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| Bromide SCHEMBL8912653 | 0.94 | HRH3 (0.37) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| SCHEMBL441543 | 0.87 | PRKCG (0.37) | SMN1; SMN2PKMHRH3PRKCGPRKCB | |
| SCHEMBL10237822 | 0.85 | ALDH1A1 (0.38) | SMN1; SMN2PKMHRH3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-10172821-B2 | Histone deacetylase inhibitors | President & Fellows of Harvard College Dana-Farber Cancer Institute, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7396828-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | SMN1; SMN2 4749/4885PKM 2800/4885HRH3 2698/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | SMN1; SMN2 4749/4885PKM 2800/4885HRH3 2698/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | SMN1; SMN2 4590/4885PKM 3338/4885HRH3 374/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | SMN1; SMN2 3990/4885PKM 1758/4885HRH3 2514/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | SMN1; SMN2 2955/4885PKM 2328/4885HRH3 373/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | SMN1; SMN2 3947/4885PKM 2378/4885HRH3 2060/4885 |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | SMN1; SMN2 4629/4885PKM 479/4885HRH3 1755/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | SMN1; SMN2 3819/4885PKM 1881/4885HRH3 1710/4885 |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | SMN1; SMN2 23/4885PKM 3828/4885HRH3 4527/4885 |
| US-10172821-B2 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC7 | SMN1; SMN2 2955/4885PKM 2328/4885HRH3 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.